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2Abstract18
KSHV is the causative agent of commonly fatal malignancies of immuno-compromised individuals,19
including primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS). A hallmark of all20
herpesviruses is their biphasic lifecycle – viral latency and the productive lytic cycle, and it is well21
established that reactivation of the KSHV lytic cycle is associated with KS pathogenesis. Therefore,22
a thorough appreciation of the mechanisms that govern reactivation is required to better23
understand disease progression. The viral protein, replication and transcription activator (RTA),24
is the KSHV lytic switch protein due to its ability to drive the expression of various lytic genes,25
leading to reactivation of the entire lytic cycle. While the mechanisms for activating lytic gene26
expression have received much attention, how RTA impacts on cellular function is less well27
understood. To address this, we developed a cell line with doxycycline-inducible RTA expression28
and applied SILAC-based quantitative proteomics. Using this methodology, we have identified a29
novel cellular protein (AT-rich interacting domain containing 3B, ARID3B) whose expression was30
enhanced by RTA and that relocalised to replication compartments upon lytic reactivation. We31
also show that siRNA knockdown or overexpression of ARID3B led to an enhancement or32
inhibition of lytic reactivation, respectively. Furthermore, DNA affinity and chromatin33
immunoprecipitation assays demonstrated that ARID3B specifically interacts with A/T-rich34
elements in the KSHV origin of lytic replication (oriLyt), and this was dependent on lytic cycle35
reactivation. Therefore, we have identified a novel cellular protein whose expression is enhanced36
by KSHV RTA with the ability to inhibit KSHV reactivation.37
3Importance38
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of fatal malignancies of39
immunocompromised individuals, including Kaposi’s sarcoma (KS). Herpesviruses are able to40
establish a latent infection, where they escape immune detection by restricting viral gene41
expression. Importantly however, reactivation of productive viral replication (the lytic cycle) is42
necessary for the pathogenesis of KS. Therefore, it is important that we comprehensively43
understand the mechanisms that govern lytic reactivation, to better understand disease44
progression. In this study, we have identified a novel cellular protein (AT-rich interacting domain45
protein 3B, ARID3B) that we show is able to temper lytic reactivation. We showed that the46
master lytic switch protein, RTA, enhanced ARID3B levels, which then interacted with viral DNA47
in a lytic cycle dependent manner. Therefore, we have added a new factor to the list of cellular48
proteins that regulate the KSHV lytic cycle, which has implications for our understanding of KSHV49
biology.50
51
4Introduction52
Infection of immune-compromised people with Kaposi’s sarcoma-associated herpesvirus (KSHV)53
is frequently linked with fatal malignancies. It is well established as the causative agent of primary54
effusion lymphoma (PEL) and Kaposi’s sarcoma (KS) and is often associated with multicentric55
Castleman’s disease (MCD) (1, 2). Like all herpesviruses, KSHV infection is lifelong and has two56
distinct phases to its life cycle; latency and the lytic cycle. Latency is associated with a highly57
restrictive viral gene expression program involving the latency-associated nuclear antigen (LANA),58
viral FLICE inhibitory protein (vFLIP), viral cyclin, kaposin and various virally-encoded miRNAs and59
together, these are required for maintenance of the KSHV genome in vitro (3) and tumorigenesis60
in vivo (2). However, reactivation from latency to the lytic cycle is indispensable for the61
pathogenesis of KS; indeed active virus replication and increased viral loads are associated with62
poorer clinical outcomes (4-6) and, there is clinical evidence that treatment of patients with63
ganciclovir (inhibitor of herpesvirus replication) significantly reduces the incidence of KS (7).64
Therefore, a comprehensive understanding of molecular mechanisms that govern KSHV65
reactivation is critical to our understanding of disease progression.66
Expression of a single viral protein, replication and transcriptional activator (RTA), is both67
necessary and sufficient for reactivation of the KSHV lytic cycle (reviewed in (8)). In vitro, RTA68
expression is stimulated by certain cellular cues such as plasma cell differentiation (9, 10) and69
hypoxia (11), and because RTA autoactivates its own promoter and drives the full lytic cycle, it is70
well established as the true KSHV lytic-switch protein (8). RTA activates transcription of lytic71
genes by directly interacting with RTA-responsive elements (RREs) found in some lytic gene72
5promoters, or indirectly via interactions with cellular transcription factors, particularly RBP-Jκ, 73
AP-1 and Oct-1 (8). The RTA protein comprises all the elements that one would expect for a74
transcriptional activator, such as nuclear localization signals (NLS), a DNA binding domain (DBD)75
and a transcriptional activation (TA) domain. Further functional domains have also been76
identified, such as a leucine zipper domain that is important for homo-tetramer formation (12),77
a serine/threonine-rich region that is subject to phosphorylation (13) and a multitude of binding78
sites for various protein-protein interactions (PPIs) (8).79
The best characterized lytic promoters that are dependent on the direct DNA binding mechanism80
are the PAN and K12 promoters (14, 15). Both genes are highly expressed during lytic reactivation,81
but their expression is prevented when DNA binding mutants of RTA are expressed (15).82
Furthermore, transfection experiments with plasmids containing the PAN promoter showed that83
RTA was essential for activating transcription, as mRNA was undetectable in its absence (16). The84
sequence elements that were found to be RTA-responsive demonstrated significant homology85
between the PAN and K12 promoters, and centered on an A/T-rich trinucleotides (17)86
reminiscent of interferon-stimulated response elements found in the promoters of interferon-87
dependent genes (18).88
There are several lytic genes that are activated via the indirect mechanism, including the RTA89
gene itself (ORF50), ORF57 (Mta), ORF6, ORF74 (vGCPR), K6 (vMIP-1), and ORF73 (LANA) (15, 19,90
20). However, whether RTA’s intrinsic DNA binding property is important for the activation of91
promoters via the indirect mechanism is a contentious issue. While some view that RTA’s ability92
to transactivate the ORF57 promoter is completely dependent on PPIs (15), others suggest that93
6cooperation between RTA-DNA interactions and PPIs enhances the activation of transcription.94
For example, in addition to the essential RBP-Jκ binding site found in the ORF57 promoter, RTA 95
binding sites have been identified that surround this region that have been characterized as96
partial palindromes of A/T-rich elements with a 5’-CANT-3’ (N = any nucleotide) repeat core97
element (21). Extensive analysis of this promoter element suggested a model whereby RTA98
recruits RBP-Jκ to its consensus binding sequence, and through tetramer formation, RTA makes 99
contacts with its cognate CANT-repeats (21). Furthermore, stabilization of this complex may100
occur via further upstream CANT-repeat interactions involving additional cellular transcription101
factors, such as AP-1 (8).102
RTA is also required to coordinate lytic replication of the KSHV genome at the cis-acting origins103
of lytic replication (oriLyt). For example, it is responsible for docking the viral pre-replication104
complex at the oriLyt (22), and this process, for unknown reasons, requires RTA-mediated105
transcription of an oriLyt-associated transcript (23, 24). Two distinct oriLyt sequences have been106
identified in the KSHV genome (oriLyt left and right); interestingly, RREs in oriLyt left share107
significant homology to those found in the PAN and K12 promoters (23). Furthermore, oriLyt108
contains an A/T-rich region consisting of various palindromic sequences in addition to a highly109
G/C-rich repeat element. Interestingly, DNA affinity studies have demonstrated that several110
cellular proteins preferentially interact with oriLyt via its A/T-rich regions (25).111
Unlike most other herpesviruses, de novo infection of cells lines with KSHV leads to latency where112
the viral genome is rapidly chromatinized and lytic genes are associated with repressive histone113
modifications (26-28), making KSHV an amenable model for studying the establishment of114
7herpesvirus latency. Furthermore, reactivation of the lytic cycle promotes various negative115
feedback mechanisms that serve to temper lytic gene expression during reactivation and, in vivo,116
these presumably function to promote the establishment or maintenance of latency. These117
include viral factors (e.g. LANA (29, 30) and viral miRNAs (31)) and cellular proteins (e.g. NF-κB 118
(32), TLE2 (33), PARP-1 (34) and HDAC1 (35)) which have been found to temper RTA119
transactivation of its target promoters and thus reactivation of the lytic cycle. Clearly, silencing120
of KSHV lytic gene expression, or inhibition of lytic DNA replication, is an important step in the121
life cycle of KSHV. Nevertheless, the mechanisms that are involved are poorly understood.122
To begin to gain an understanding of how RTA expression impacts on the cellular proteome, we123
employed a global quantitative proteomics approach using stable isotope labeling of amino acids124
in cell culture coupled to tandem mass spectrometry (SILAC-MS/MS). Quantitative proteomics,125
using various platforms, is a powerful method that has been employed by various laboratories,126
including our own (36-38), to investigate virus-host interactions (recently reviewed in (39) and127
(40)). Using this approach we identified a novel protein, A/T-rich interacting domain 3B (ARID3B),128
whose expression was enhanced by RTA and that regulated the KSHV lytic cycle. ARID3B, so called129
as it contains an A/T-rich interactive domain (ARID), belongs to a family of proteins involved in130
the regulation of gene expression. The ARID of ARID3A (a paralogue of ARID3B that functions as131
a B cell activator) has been shown to preferentially bind AATTAA sequences (41, 42); as this132
domain shares 89.9% sequence identity with that found in ARID3B, it suggests there is functional133
conservation between these proteins.134
8As a transcription factor (43, 44), ARID3B promotes survival during development (44-46), and it135
is these properties that link it with various malignancies (43, 47-52). Very little else is known136
about ARID3B; however, we reasoned that its prosurvival properties may be important during137
the KSHV lytic cycle and it might promote lytic gene expression, thus explaining its RTA-mediated138
enhanced expression. However, we found that ARID3B inhibited lytic reactivation, and, as it139
preferentially bound to regions containing A/T-rich elements in oriLyt, we consider the possibility140
that it either prevents oriLyt-dependent gene expression or it blocks access to proteins essential141
for viral genome replication.142
9Materials and Methods143
Cell lines, plasmids and transfections. TREx-BCBL-1-RTA cells (a kind gift from Dr. Jae Jung,144
University of Southern California) are a BCBL-1-based cell line that has been engineered to145
inducibly express exogenous Myc-tagged RTA by the addition of 1 µg/ml doxycycline hyclate,146
leading to a robust reactivation of the full KSHV lytic cycle (53); these were cultured in RPMI-1640147
(Lonza) supplemented with 10% FBS (Life Technologies). Inducible SLK-BAC16 cells (iSLK-BAC16;148
also a gift from Dr. Jae Jung) were grown in DMEM (Lonza) supplemented with 10% FBS (Life149
Technologies). These maintain a latent infection with bacterial artificial chromosome 16-150
(BAC16)-derived KSHV (54). The parental SLK cell line, originally considered to be KSHV-negative151
endothelial cells derived from a KS patient, were subsequently found to be a contaminant of a152
renal carcinoma cell line Caki1 (55). Nevertheless, they are widely used as a model for the study153
of KSHV biology. Initially, these cells were engineered to inducibly express RTA (iSLK) following154
the addition of doxycycline (56) and subsequently transfected with BAC16 and selected based on155
BAC-derived puromycin resistance (54). This cell line was demonstrated to support an authentic156
latent infection, and induction of the lytic cycle (with 1 µg/ml doxycycline hyclate) leads to the157
release of infectious virus (54).158
HEK 293T cells were used for reinfection assays as previously described (57). HEK293 rKSHV.219159
cells (58) maintains KSHV as a latent infection and was generated by infecting HEK293T cells with160
a recombinant KSHV that contains a constitutively active puromycin resistance and GFP gene,161
and an RFP gene that is fused to an RTA-responsive lytic cycle (PAN) promoter (not utilized in this162
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study). Both HEK 293T-based cell lines were maintained in DMEM (Lonza) supplemented with 10%163
FBS (Life Technologies).164
To generate cells with inducible N-terminal FLAG-His-tagged RTA expression (iRTA-293), RTA was165
amplified from pRTS-ORF50 (14) (forward primer: 5’-166
ATCTTAAGGCCACCATGGATTATAAAGATGACGATGACAAGCATCATCATCATCATCATGCGCAAGATG167
ACAAGGGTAAG-3’, reverse primer: 5’-ATCTCGAGTCAGTCTCGGAAGTAATTACG-3’) and ligated in168
to the AflI-XhoI sites of pcDNA5-FRT-TO (Life Technologies) to generate pcDNA5-FH-RTA.169
Functionality of this vector was demonstrated due to its ability to reactivate the KSHV lytic cycle170
following its transfection. Flp-In-293 cells (Life Technologies) were transfected along with pOG44171
(flp recombinase) and subsequently selected using Hygromycin B following the manufacturer’s172
protocol (Life Technologies). Clonal populations were generated by limiting dilution under173
Hygromycin B selection and clones with tightly regulated expression and normal growth174
properties (compared to parental cells) were selected. RTA expression was induced following175
treatment with 1 µg/ml doxycycline hyclate for the indicated times. iRTA-293 cells were176
maintained in DMEM (Lonza) supplemented with 10% FBS (Life Technologies).177
The vector expressing C-terminally FLAG-tagged ARID3B was generated by PCR amplification178
using an ARID3B-containing plasmid (kind gift from Dr. Karen Cowden Dahl, Indiana University)179
as template (Forward primer: 5’-CGCGGATCCAAGCGATGGAGCCACTTCAGCAGCAGCAGCA-3’,180
reverse primer: 5’-181
CGCGAATTCTCACTTATCGTCGTCATCCTTGTAATCGAGGGACCAGCTGGTGGAGGGCTC-3’). Products182
were digested and ligated into the BamHI and EcoRI sites of pcDNA3 (pcDNA3-ARID3B-FLAG).183
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FLAG-tagged SRAG was a kind gift from Prof Stuart Wilson (University of Sheffield). Expression184
constructs were verified by DNA sequencing.185
For transfections, cells were plated into 6-well plates and transfections routinely used 1 μg 186
plasmid DNA and Lipofectamine 2000 (Life Technologies) following the manufacturer’s187
instructions.188
To determine the effects of overexpressed proteins on virus reactivation efficiencies, iSLK-BAC16189
cells were transfected for 24 h and the lytic cycle was induced by doxycycline treatment for a190
further 24 h. Samples were processed for immunoblot analysis (see later).191
Stable isotope labelling of amino acids in cell culture (SILAC)-proteomics. iRTA-293 cells were192
grown in “heavy”-labeled media containing stable isotopes of arginine (R) and lysine (K) (R10K8;193
DMEM-16, Dundee Cell Products) or “light”-labeled media (R0K0; DMEM-14, Dundee Cell194
Products) supplemented with 10% dialysed FCS (DS1003, Dundee Cell Products) for two weeks.195
Cells were grown to 80-90% confluency in 10 cm dishes that included poly-L-lysine coated196
coverslips, used to verify RTA expression by immunofluorescence (see later). RTA expression was197
induced for 12 h following treatment of heavy-labeled cells with 1 µg/ml doxycycline hyclate. To198
reduce sample complexity, and to investigate how RTA expression impacts on the nuclear199
proteome, labeled cells were fractionated (verified by immunoblotting; see later). After rinsing200
the monolayer with PBS, 1x107 cells from each culture were lysed in 5 ml cytoplasmic lysis buffer201
containing 20 mM Tris (pH 7.4), 100 mM NaCl, 0.5 mM EDTA, 0.5 % NP-40 and 1x protease202
inhibitor cocktail (Roche) for 20 min at 4°C. The nuclei were pelleted at 2000 xg for 5 min at 4°C203
and the cytoplasmic fraction was removed and stored. Nuclei were washed three times in204
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cytoplasmic lysis buffer, then nuclear proteins were extracted using 200 µl RIPA buffer by205
repeated pipetting and storage on ice for 15 min. Insoluble material was pelleted at 12,000 xg206
for 10 min and the supernatant was removed.207
Equal amounts of protein from unlabeled and labeled samples were combined prior to protein208
digestion. Briefly, samples were reduced 50 mM DTT 1x NUPAGE LDS loading buffer, and then209
separated by one-dimensional SDS-PAGE (4-12% Bis-Tris Novex mini-gel, Life Technologies) and210
visualized by colloidal Coomassie staining (Novex, Life Technologies). The entire protein gel lanes211
were excised and cut into 10 slices each. Every gel slice was subjected to in-gel digestion with212
trypsin overnight at 37°C. The resulting tryptic peptides were extracted by formic acid (1%) and213
acetonitile, lyophilized in a speed vac and resuspended in 1% formic acid. Trypsin-digested214
peptides were separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system.215
On average 0.5 µg was loaded with a constant flow of 5 µl/min onto an Acclaim PepMap100216
nanoViper C18 trap column (100 µm inner diameter, 2cm; Themro Scientific). After trap217
enrichment, peptides were eluted onto an Acclaim PepMap RSLC nanoViper, C18 column (75 µm,218
15 cm; Thermo Scientific) with a linear gradient of 2–40% solvent B (80% acetonitrile with 0.08%219
formic acid) over 65 min with a constant flow of 300 nl/min. The HPLC system was coupled to a220
linear ion trap Orbitrap hybrid mass spectrometer (LTQ Orbitrap Velos, Thermo Scientific) via a221
nano-electrospray ion source (Thermo Scientific). The spray voltage was set to 1.2 kV, and the222
temperature of the heated capillary was set to 250°C. Full-scan MS survey spectra (m/z 335–1800)223
in profile mode were acquired in the Orbitrap with a resolution of 60,000 after accumulation of224
1,000,000 ions. The fifteen most intense peptide ions from the preview scan in the Orbitrap were225
fragmented by collision-induced dissociation (normalized collision energy, 35%; activation Q,226
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0.250; and activation time, 10 ms) in the LTQ after the accumulation of 10,000 ions. Maximal227
filling times were 1,000 ms for the full scans and 150 ms for the MS/MS scans. Precursor ion228
charge state screening was enabled, and all unassigned charge states as well as singly charged229
species were rejected. The lock mass option was enabled for survey scans to improve mass230
accuracy. Data were acquired using the Xcalibur software. The raw mass spectrometric data files231
obtained for each experiment were collated into a single quantitated data set using MaxQuant232
(version 1.2.2.5) and the Andromeda search engine software . Enzyme specificity was set to that233
of trypsin, allowing for cleavage N-terminal to proline residues and between aspartic acid and234
proline residues. Other parameters used were: (i) variable modifications, methionine oxidation,235
protein N-acetylation, Gln to pyro-Glu; (ii) fixed modifications, cysteine carbamidomethylation;236
(iii) database: target-decoy human MaxQuant (ipi.HUMAN.v3.68); (iv) heavy labels: R10K8; (v)237
MS/MS tolerance: FTMS- 10 ppm , ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) maximum238
missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false discovery rate (FDR),239
1%. Peptide ratios were calculated for each arginine- and/or lysine-containing peptide as the240
peak area of labelled arginine/lysine divided by the peak area of nonlabelled arginine/lysine for241
each single-scan mass spectrum. Peptide ratios for all arginine- and lysine-containing peptides242
sequenced for each protein were averaged. Data were normalized using 1/median ratio value for243
each identified protein group per labelled sample. Pathway analysis was performed using DAVID244
Bioinformatics Resources [https://david.ncifcrf.gov/] (59, 60) using proteins that were at least 2-245
fold differences.246
Immunoprecipitation and Immunoblotting. Immunoprecipitation assays have been described247
previously (61). For immunoblot analysis, cells were washed in PBS and proteins extracted in lysis248
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buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40 and 1x protease inhibitor cocktail249
(Roche) for 15 min on ice and clarified by centrifugation at 12,000 xg for 10 min, 4°C. For the250
detection of ARID3B by immunoblotting, we found that sonication prior to loading improved251
detection. SDS-PAGE and immunoblotting of normalized protein concentrations followed252
standard techniques using the following antibodies: rabbit pAb anti-FLAG-tag (1:1000; Sigma),253
mouse mAb anti-ORF57 207.6 (1:1000; Santa Cruz), RTA, rabbit antisera (1:400; gift from Prof.254
David Blackbourn, University of Surrey), mouse mAb anti-GAPDH (1:5000; Sigma), mouse mAb255
anti-Lamin B1 (1:1000; Santa Cruz), rabbit αARID3B (1:200; Abcam), anti-ORF59 (Autogen 256
Bioclear), sheep anti-KSHV minor capsid protein (mCP 1:1000; Exalpha Biologicals, Inc.). Proteins257
were detected by chemiluminescence (using HRP-conjugated secondary antibodies) and signals258
were captured digitally using the ChemiDoc MP Imager (Bio-Rad) that ensures signal saturation259
does not occur. ImageLab software version 4.1 (Bio-Rad) was used to select and determine the260
background-subtracted density of the bands in all blots and these were normalized against261
expression of GAPDH.262
Indirect immunofluorescence microscopy. As previously described (62), coverslips were coated263
with poly-L-lysine and TREx-BCBL-1-RTA cells were plated (1x106 per well of a 12-well plate) and264
doxycycline hyclate-treated (1 µg/ml) for 18 h at 37°C. Following doxycycline hyclate treatment265
of SILAC-labeled iRTA-293 cells (see above), coverslips were removed from the 10 cm dishes and266
placed in a humidity chamber. Cells were gently washed with PBS, fixed using 4% formaldehyde267
(in PBS) for 10 min, permeabilized with PBS, 1% Triton X-100 for 10 min and washed three times268
with PBS as previously reported (62). Primary antibodies were diluted in PBS, 2% BSA, added to269
cells and incubated in humidity chambers for 2 h at 37°C or overnight at 4°C followed by 5 washed270
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with PBS. The appropriate secondary antibodies (Alexa Fluor 488 or 594; Life Technologies) were271
diluted 1:500 in PBS, 2% BSA and incubated with cells for 1 h at 37°C followed by 5 washed with272
PBS. Coverslips were mounted in VECTORSHEILD with DAPI (Vectorlabs).273
Incorporation of EdU was performed using a Click-iT EdU Imaging Kit (Life Technologies) (62).274
Briefly, 1x106 TREx-BCBL-1-RTA cells were treated doxycycline and the cells were plated onto275
poly-L-lysine-coated coverslips. After 16 h, cells were pulsed for 45 min with 10 μM EdU, washed, 276
fixed and permeablized according to the manufacturer’s recommendations. After detection of277
EdU (according to the manufacturer’s protocol), the cells were washed and further incubated278
with the indicated antibody for 1 h at 37°C, washed again and incubated with Alexa Fluor 488279
goat anti-rabbit antibody (Life Technologies; 1:500 in PBS, 2% BSA) for 1 h at 37°C. Finally, DNA280
was stained using Hoechst 33342 (1:2000 in PBS) and mounted in VECTORSHIELD (Vectorlabs).281
Images were captured using an LSM510 or LSM700 laser scanning microscope (Carl Zeiss) and282
processed using ZEN imaging software (Carl Zeiss).283
Antibodies included: rabbit anti-FLAG (1:250; Sigma), mouse anti-Myc tag 9E10 (1:250; Sigma),284
RTA rabbit antisera (1:100), rabbit anti-ARID3B (1:100; Abcam).285
Quantitative PCR. For RT-qPCR, total cellular RNA was extracted from cells using Trizol (Life286
Technologies) according to the manufacturer’s instructions and contaminating DNA was287
removed using the DNA-free kit (Ambion). Complimentary DNA (cDNA) was generated from 1 μg 288
RNA in 20 μl reaction volumes using M-MuLV reverse transcriptase (RT; New England Biolabs) 289
according to the manufacturer’s recommendations with 5 ng oligo(dT). In parallel, negative290
control reactions were performed for each RNA by omitting RT in order to confirm that291
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quantification represented cDNA and not contaminating DNA. For quantification of viral DNA,292
1x106 cells were treated with doxycycline hyclate, or left untreated. At 72 h post-reactivation,293
total DNA was extracted using a DNA Minikit (Qiagen) and quantified by UV spectrophotometry.294
Viral DNA was quantified using primers specific for the ORF57 gene. Quantitative PCR reaction295
mixes (20 μl) included 1x SensiMix SYBR green master mix (Bioline), 0.5 μM each primer and 1 μl 296
cDNA or 3.4 ng total DNA. Cycling was performed in a RotorGene Q machine (Eppendorf) and297
included an initial 10 min denaturation step at 94°C, followed by 40 cycles of 30 s at 94°C, 30 s at298
60°C and 30 s at 72°C. Melting curve analysis was performed between 65 and 95°C (with 0.2°C299
increments) to verify amplicon specificity. Quantification of GAPDH mRNA (qRT-PCR) or GAPDH300
DNA (virus reactivation) was used to normalize between samples, and the average cycle301
threshold (CT) was determined from three independent samples from independent cultures.302
Calculations were made using the ΔΔCT method. 303
RNAi. Conditions for siRNA knockdown of ARID3B followed previously reported protocols (57).304
Briefly, 20 nM of SMARTpool: ON-TARGETplus ARID3B siRNA (L-012219-00-0005, Dharmcon) or305
Hs_ARID3B_3 FlexiTube GeneSolution (GS10620, Qiagen), or scramble control siRNA (siRNA306
controls from the respective manufacturer were used as controls), were transfected into iSLK-307
BAC16 cells for 72 h. For experiments that required reactivation of the lytic cycle, doxycycline308
was added to cells for 24 h, as stated above.309
In vitro DNA affinity assay. Assays were performed according to (25), with minor modifications:310
HEK293 rKSHV.219 cells in 6-well plates were transfected with pcDNA3-ARID3B-FLAG and the311
lytic cycle was induced for 24 h. OriLyt sequences 3F, 9F and 11F were amplified from the KSHV312
17
genome using 5’-Biotinylated primers (primer sequences already described (25)) and a control313
region of the KSHV genome (RTA gene body: forward primer 5’-GTCTACCTTCCGAGGATTATGG-3’,314
reverse primer : 5’-GATTCTGGCATGAGACCGCTTC-3’). PCR products were incubated with315
Dynabeads M-280 Streptavidin according to the manufacturer’s recommendations (Life316
Technologies). Affinity purification followed the previously described methods (25).317
Chromatin immunoprecipitation. Cells were cross-linked with 1% formaldehyde (Thermo318
Scientific, no. 28908) for 10 min at room temperature. Glycine was added to a final concentration319
of 125 mM to stop the cross-linking reaction, and the samples were incubated for another 5 min320
at room temperature. Cells were washed twice with ice-cold PBS and lysed in FastChIP buffer (50321
mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5 mM DTT, 0.5% Igepal CA-630, 1.0% Triton322
X-100) containing protease inhibitors (Roche) as described (63, 64). Isolated nuclei were323
resuspended in SDS lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% SDS) and the samples324
were incubated on ice for 15 min. Nuclear lysates were sonicated for 10 min in a Diagenode325
Bioruptor Pico (30 sec on-off intervals) and cleared by centrifugation for 30 min at 20,000×g and326
4°C. Sheared chromatin from 9×106 cells (180µl) was combined with nine volumes of ChIP dilution327
buffer (16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 0.01% SDS)328
and subjected to immunoprecipitation for 16 h at 4°C with gentle rotation using 13 µl of Rabbit329
anti-ARID3B antibody (Bethyl Laboratories, no. A302-564A-M) or 4 µg of normal rabbit IgG.330
Samples were centrifuged for 10 min at 20,000×g, 4°C to remove any precipitated material, and331
the supernatants were combined with 20 µl Magna ChIP Protein A Magnetic Beads (Millipore, no.332
16-661) and incubated for 2 h at 4°C with gentle rotation. Immune complexes were washed with333
1 ml each of low-salt buffer (20 mM Tris-HCl [pH 8.1], 150 mM NaCl, 2 mM EDTA, 1% Triton X-334
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100, 0.1% SDS), high-salt buffer (20 mM Tris [pH 8.1], 0.5 M NaCl, 2 mM EDTA, 1% Triton X-100,335
0.1% SDS), lithium chloride (LiCl) buffer (10 mM Tris [pH 8.1], 0.25 M LiCl, 1 mM EDTA, 1% Igepal-336
CA 630, 1% deoxycholic acid), and twice with TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) buffer.337
Elution of the chromatin-antibody complexes was carried out by incubation with 150 μl freshly 338
prepared elution buffer (100 mM NaHCO3, 1% SDS) containing 1.5 µl Proteinase K (Roche, no. 03339
115 887 001) at 62°C for 2 h, followed by a 10 min incubation step at 95°C. DNA was purified340
using the NucleoSpin Gel and PCR Clean-up Kit from Macherey-Nagel (no. 740609) following their341
DNA clean-up protocol for samples containing SDS. DNA was eluted with 90 µl Buffer NE and 5 µl342
of the DNA solution were used as template DNA for qPCR using primers specific for the A/T-rich343
region of oriLyt left (forward primer: 5’-CCCTCCTTTGTTTTCCGGAAG-3’ and reverse primer:344
5’CTCATCGGGCCCTATTATAAAG-3’) and the RTA coding region (forward primer 5’-345
GTCTACCTTCCGAGGATTATGG-3’, reverse primer : 5’-GATTCTGGCATGAGACCGCTTC-3’).346
347
19
Results348
ARID3B expression is enhanced by RTA. To investigate the impact of the lytic-switch protein RTA349
expression on the host proteome, we developed a cell line with doxycycline-inducible RTA350
expression (iRTA-293) and applied global proteomics using stable isotope labeling of amino acids351
in cell culture (SILAC). After metabolically labelling cells in media containing different stable352
isotopes of arginine (R) and lysine (K) (e.g. R10K8 (heavy) or R0K0 (light)) for two weeks, we353
induced RTA expression from heavy-labeled cells for 12 h while leaving light-labeled cells354
untreated. We tested RTA expression by immunofluorescence and then fractionated cells into355
cytoplasmic and nuclear fractions that were validated by immunoblot analysis using cytoplasmic356
and nuclear markers (Fig. 1A-B). Both these assays demonstrated the expected nuclear357
expression of RTA. We combined the nuclear fractions (heavy vs. light) 1:1 and applied LC-MS/MS358
(Dundee Cell Products, see Materials and Methods). Identified and quantified proteins with a359
minimum of two unique peptides and a fold change in abundance of >2-fold were taken forward360
for bioinformatics analyses. KEGG pathway analysis of the nuclear proteome of proteins361
increased in abundance upon RTA expression (using DAVID Bioinformatics Resources (59, 60))362
identified various pathways one might expect to be modulated upon RTA expression (e.g. cell363
cycle control (65) and DNA replication (24); (Fig. 1C). However, various DNA damage response364
(DDR) pathways were also identified in addition to ubiquitin-mediated proteolysis (specifically365
Cullin-RING ubiquitin ligases [CRLs]). A cellular mechanism that regulates CRLs (66-68) and many366
of the listed DDR pathways (69-71) is the ubiquitin-like modification NEDDylation. Of note, we367
recently showed that blocking NEDDylation in cells latently infected with KSHV resulted in the368
activation RTA expression, but inhibited viral DNA replication (62). Interestingly, a similar369
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observation (with regards to effects on viral gene expression and viral DNA replication) was370
recently reported for the betaherpesvirus, human cytomegalovirus (HCMV); blocking of371
NEDDylation also led to increased immediate early gene expression in the absence of viral DNA372
replication (72). Furthermore, both of these reports showed that Cullin 4B was particularly373
important for regulating viral gene expression (62, 72).374
In addition to investigating cellular pathways associated with RTA expression, we compiled a list375
of the top 15 proteins that showed increases in abundance in RTA expressing cells (Table 1).376
Interestingly, a number of proteins associated with transcriptional repression were identified377
(cell division cycle-associated 7-like (15.5-fold increase), Polycomb group protein378
Lethal(3)malignant brain tumor-like protein 3 (5.7-fold increase) and lysine-specific demethylase379
2A (5.2-fold increase)). We also note that RTA expression was associated with an increased380
abundance of protein LYRIC (7.0-fold increase) that has been shown to activate NF-κB (Table 1); 381
intriguingly, these data suggest that RTA is associated with the expression of factors that one382
would predict to inhibit RTA’s transcriptional activity. In accordance with this, we also applied383
Ingenuity Pathways Analysis (IPA) to the same dataset, and the top canonical pathway identified,384
in addition to cell cycle control, DNA replication and various DNA damage pathways, was385
‘transcriptional repression’ (Table 2). We are currently investigating some of these observations386
and in this report we focus on the novel protein ARID3B (7.5-fold increase). There are a number387
of features that led us to investigate ARID3B. Relatively little is known about this protein, and388
using KSHV as a tractable model system, we wished to further study its function. It has been389
shown that ARID3B functions as a transcription factor linked with prosurvival mechanisms during390
developmental processes (44-46), and these functions may be beneficial for reactivation.391
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Furthermore, ARID domains have been described as DNA binding domains that favor A/T-rich392
sequences; given the predominance of A/T-rich elements in regulatory regions of the KSHV393
genome (RREs, oriLyt etc.), we hypothesized that ARID3B would cooperate with RTA during394
reactivation of the lytic cycle.395
To investigate how RTA expression might lead to an increase in ARID3B levels, we induced RTA396
expression in iRTA-293 cells in addition to reactivating the lytic cycle in TREx-BCBL-1-RTA cells397
(see Materials and Methods for a description of the cell lines used in this study). We performed398
RT-qPCR analysis and found that RTA, and lytic reactivation, led to a small but reproducible399
increase in ARID3B mRNA expression (ca. 2.5-fold increase, Fig. 2A). We also reactivated the lytic400
cycle in iSLK-BAC16 and TREx-BCBL-1-RTA cells and performed immunoblot analyses using401
antibodies specific for ARID3B (Fig. 2B). This showed that lytic reactivation led to an approximate402
1.5 - 2-fold increase in ARID3B expression (Fig. 2C). These changes are modest, but likely reflect403
the superior sensitivity of mass spectrometry, and the semi-quantitative nature of immunoblot404
data. Together, these data demonstrate that RTA, and the KSHV lytic cycle, enhances ARID3B405
expression at both the RNA and protein level.406
ARID3B is relocalized during reactivation. Given that ARID3B expression levels were influenced407
by RTA expression and lytic reactivation, we next asked whether it was involved in regulating the408
KSHV lytic cycle. Using an immunofluorescence microscopy approach, we showed that in latently409
infected TREx-BCBL-1-RTA cells, ARID3B expression displayed a pan-nuclear (excluding nucleoli)410
localization (Fig. 3A; -Dox. (latent)). However, upon lytic reactivation, ARID3B is relocalized to411
discrete, RTA-positive foci, with close proximity to the nuclear periphery (Fig. 3A; +Dox. (lytic),412
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compare the RTA-positive, reactivated cells to the RTA-negative cell in the same field of view),413
reminiscent of replication compartments (also known as replication and transcription414
compartments, RTCs). Replication compartments are distinct, RTA-positive foci found at the415
nuclear periphery associated with newly replicated viral DNA (that are observed via incorporation416
of BrdU or EdU that specifically marks viral DNA due to KSHV’s ability to block cellular DNA417
replication during reactivation). We performed an independent experiment to ask if ARID3B did418
indeed relocalize to these foci. Consequently, ARID3B was again shown to co-stain with RTA and419
to colocalize with EdU-positive foci (Fig. 3B) suggesting that it did indeed relocalized from a pan-420
nuclear pattern into KSHV replication compartments upon lytic reactivation.421
ARID3B modulates the KSHV lytic cycle. To investigate if ARID3B influenced the KSHV lytic cycle,422
we transfected iSLK-BAC16 cells with two separate pools of ARID3B-targeted or scramble control423
siRNAs and induced the lytic cycle with doxycycline for 24 h. Given that ARID3B has been424
suggested to function as a transcription factor, we anticipated that it might be important for425
enhancing RTA-mediated expression of lytic genes. Using RT-qPCR we demonstrated an426
approximately 50% knockdown of ARID3B. This was sufficient to enhance lytic gene expression427
between 1.5 – 2.5-fold, as shown for lytic genes ORF57 and gB (Fig. 4A), suggesting that ARID3B428
might actually inhibit lytic gene expression. We noticed that the two siRNAs had slightly different429
effects on lytic gene expression; these two siRNA preparations were mixtures of three different430
sequences, and it might be that one of these more potently targets ARID3B. However, we cannot431
fully explain this as the current time, and this difference was not observed in other assays with432
this set of siRNAs. ARID3B knockdown was also associated with an approximate 2-fold increase433
in lytic protein expression (Fig. 4B-C). Accordingly, ARID3B knockdown, followed by reactivation434
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of the lytic cycle, also led to a significant enhancement of KSHV genome replication compared to435
cells transfected with a scramble control siRNA (Fig. 4D). Importantly, knockdown in latently436
infected cells did not activate viral DNA replication (Fig. 4D) suggesting that RTA expression, or437
the lytic cycle were required to activate ARID3B’s inhibitory properties.438
To ask if the increases in lytic cycle-associated expression and genome replication led to an439
enhanced productive infection, we harvested and clarified media from iSLK-BAC16 cells that had440
been transfected with ARID3B siRNA and reactivated with doxycycline. We transferred this media441
to KSHV-negative cells (HEK 293T), and 24 h later, purified total cellular RNA. Using RT-qPCR442
analysis of the KSHV ORF57 gene as a measure of virus infection, we demonstrated knockdown443
of ARID3B led to an enhancement of virus infection, suggesting that ARID3B knockdown led to444
an increase of released virions (Fig. 4E). Together, these data showed that ARID3B knockdown445
enhanced the KSHV lytic cycle, contrary to our initial hypothesis. However, these differences446
were modest given our inability to reduce ARID3B expression more than 50-60%. Therefore, we447
took an alternative approach and asked if ARID3B overexpression could inhibit KSHV reactivation.448
Here we showed that transfection of FLAG-tagged ARID3B, but not FLAG-SRAG (used as a control449
as we know its expression does not modulate lytic reactivation), in iSLK-BAC16 cells for 24 h,450
followed by reactivation of the lytic cycle, inhibited the expression of KSHV lytic genes (Fig. 4F).451
Together, these data demonstrate that ARID3B is able to modulate KSHV reactivation, and not452
enhance it, as originally predicted.453
454
ARID3B interacts with an A/T-rich region of oriLyt in a lytic reactivation-dependent manner. To455
investigate a potential mechanism whereby ARID3B tempered KSHV lytic reactivation, we tested456
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the possibility that ARID3B interacted with RTA and inhibited its function. RTA interacts with457
various cellular proteins that are known to be inhibitory, including PARP1 (34), TLE2 (33) and458
HDAC1 (35). However, co-immunoprecipitation assays demonstrated that while RTA interacted459
with a known binding partner ORF59 (22), it did not interact with ARID3B (Fig. 5). Next, we460
reasoned that ARID3B, as a DNA binding protein, might interact with viral genomes. Furthermore,461
due to its predicted preference for A/T-rich sequences, and the existence of these sequences in462
oriLyt, we focused our attention to this region of the KSHV genome. We performed a DNA affinity463
assay that has previously been reported as a method for identifying proteins involved in KSHV464
reactivation (25). Biotinylated PCR products that spanned oriLyt were amplified from KSHV DNA465
(Fig. 6A) were bound to streptavidin-coated beads and incubated with lysate from reactivated466
HEK293T-rKSHV.219 cells that had been transfected with FLAG-ARID3B 24 h earlier. Compared467
to control DNA (amplified from the RTA coding region), and a central G/C-rich repeat region (“9F”)468
we found that ARID3B preferentially bound to “3F” which contains the A/T-rich region of KSHV469
oriLyt (Fig. 6A). ARID3B also bound to “11F” which contained the RTA-responsive element (RRE),470
although this appeared to be slightly reduced when compared to the 3F region. Interestingly, it471
was shown previously that many host and viral proteins involved in KSHV reactivation specifically472
bind these two regions in oriLyt (25).473
We confirmed this result using chromatin immunoprecipitation (ChIP) assays using TREx-BCBL-474
1-RTA cells. This allowed to us investigate whether ARID3B interacted with the KSHV genome in475
infected cells, in addition to asking if this was linked with reactivation of the lytic cycle. Using an476
antibody that has previously used in ChIP assays (43), we showed that endogenous ARID3B477
interacted preferentially with the A/T-rich region of oriLyt (3.5-fold enrichment over control IgG478
25
antibody), and not within the RTA gene (Fig. 6B). Furthermore, we showed that this interaction479
was dependent on reactivation of the KSHV lytic cycle as no binding (above control IgG antibody)480
was observed in latent cells (Fig. 6B). These data, together with data in Fig. 2 (lytic cycle-481
associated relocalization) and Fig. 4 (knockdown of ARID3B does not induce viral DNA replication),482
suggest that ARID3B influences KSHV biology only upon reactivation of the lytic cycle.483
484
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Discussion.485
It is well established that KSHV is the etiologic agent of various malignancies in immune-486
compromised individuals, particularly those infected with HIV. Indeed, KS is the most prevalent487
malignancy in regions with endemic HIV and, for HIV sufferers, is one of a number of diseases488
that are used as a guideline for the diagnosis of AIDS (i.e. KS is considered an AIDS-defining489
disease) (2). Importantly, various reports, including data from clinical studies, link reactivation of490
the KSHV lytic cycle with the pathogenesis of KS. Therefore, it is imperative that we understand491
the mechanisms that regulate this aspect of KSHV biology. RTA, the KSHV lytic switch protein, is492
both necessary and sufficient for reactivation of the lytic cycle (8). While we have a relatively493
good understanding of how RTA drives the viral transcriptional program responsible for lytic494
reactivation (8), how RTA influences cellular responses is less well understood. In this report we495
developed a cell line with inducible RTA expression and, by applying a quantitative proteomics496
approach, used it to investigate what impact RTA expression has on the cellular proteome.497
We identified a number of cellular pathways that were associated with RTA expression, and some498
of these are the focus of current research. Of note, ubiquitin-mediated proteolysis was one of499
the gene ontology terms included in our bioinformatics analyses. We, and others, have recently500
reported the importance of this pathways for regulating herpesvirus gene expression, and501
demonstrated that this pathway represents a potential therapeutic target for the treatment of502
herpesvirus disease (62, 72). In addition to studying cellular pathways, we generated a list of the503
top 15 proteins based on increased protein abundance in RTA-expressing cells. In this report, we504
focused on a little-known protein ARID3B. We initially hypothesized that, as a prosurvival505
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transcription factor (43, 44), this protein would cooperate with RTA during reactivation of the506
lytic cycle. However, we actually found that ARID3B played an inhibitory role, and its expression507
was associated with modulating lytic reactivation.508
A hallmark of all herpesviruses is their ability to establish a latent infection characterized by a509
highly restricted gene expression program. This is an incredibly effective means of evading510
detection by the immune system, and ensures infection is maintained throughout the life of the511
host. Nevertheless, periodic reactivation of the lytic cycle is necessary in order to maintain the512
population of infected cells. However, the lytic cycle must be exquisitely regulated so that it does513
not lead to uncontrolled virion production and severe disease in its host. We observed that upon514
RTA expression, or reactivation of the lytic cycle, ARID3B expression was increased both at the515
mRNA and protein level. To ascertain if this had functional consequences for KSHV reactivation,516
we performed a series of experiments that showed ARID3B was able to block reactivation. This517
included siRNA-mediated knockdown of ARID3B, which resulted in enhanced lytic gene518
expression, lytic protein expression and an increase in genome replication. Furthermore,519
knockdown of ARID3B potentially led to an increase in virion production, as suggested by520
reinfection assays. As an alternative approach, overexpression of ARID3B significantly abrogated521
lytic protein expression. Importantly, knockdown of ARID3B in latently infected cells did not522
reactivate the lytic cycle, suggesting that it was not involved in the maintenance of latency.523
Therefore, RTA-mediated activation of ARID3B specifically served to regulate lytic reactivation;524
however, it is also possible that this inhibitory function may be important during the525
establishment phase of latency.526
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KSHV reactivation leads to the upregulation of several negative feedback processes that temper527
the lytic cycle, many of which center on abrogating RTA’s interaction with RBP-Jκ (required for 528
transactivating various lytic gene promoters via the ‘indirect’ mechanism (8)). For example, and529
in a similar vein to the observed RTA-enhanced ARID3B expression, RTA enhances the expression530
of the co-repressor transducin-like enhancer of split 2 (TLE2) that blocked lytic reactivation by531
competing with RBP-Jκ for the same binding site in RTA (33) (we did not identify TLE2 in our 532
datasets). Lytic reactivation also promotes nuclear translocation of the transcription factor NF-533
κB, which in turn negatively regulates lytic cycle-associated gene expression by competing with 534
RTA for RBP-Jκ binding (32, 73, 74). Furthermore, activated NF-κB is required for the expression 535
of latency-associated genes (e.g. LANA, vFLIP, vCyclin), and LANA has been shown to inhibit lytic536
reactivation, again, by interfering with RTA-RBP-Jκ interactions (75, 76). Additional negative 537
regulatory mechanisms involve RTA interactions with histone deacetylase enzymes HDAC1 (35)538
and SIRT1 (77), which limits RTA’s ability to activate lytic gene transcription. We do not currently539
know how RTA led to increases in ARID3B expression. As a transcription factor, RTA may drive540
the expression of ARID3B; it may also be possible that RTA induces ARID3B expression indirectly.541
Here, two possibilities exist: i) RTA expression may promote a cellular response that is linked to542
ARID3B expression or ii) RTA may sequester a repressor that would normally silence ARID3B. As543
there are no reports describing the regulation of ARID3B expression, it is not possible to go544
beyond speculation.545
Commencement of the lytic cycle leads to a dramatic remodelling of the cell nucleus and the546
formation of discrete foci (termed replication compartments) where viral transcription, genome547
replication and capsid assembly takes place (78). For KSHV, the formation of replication548
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compartment was recently shown to be dependent on the chaperone function of Hsp70 proteins549
(57). We observed that, upon lytic reactivation, ARID3B relocalized from a pan-nuclear pattern,550
to replication compartments as shown by its colocalization with RTA and EdU. Of note, it was also551
recently shown that lytic reactivation induced the relocalization of TLE2 in to replication552
compartments (33), highlighting a common feature among negative regulators of the lytic cycle.553
This suggested that ARID3B might inhibit reactivation by interacting with a protein required for554
lytic reactivation (cellular or viral), or the viral genome, although these scenarios are not555
necessarily mutually exclusive. Interestingly, RTA and ARID3B did not interact. This was556
somewhat surprising; however, as a DNA binding protein, an interaction with RTA may not be557
necessary for it to associate with reactivated KSHV. Therefore, unlike the majority of lytic cycle558
regulators that have been shown to interact directly with RTA, ARID3B performs this task via a559
different mechanism.560
We reasoned that ARID3B, as a DNA binding protein, might interact with viral genomes.561
Particularly, given its proposed preference for A/T-rich sequences and the presence of these562
sequences in oriLyt, we considered the possibility that ARID3B binds to this region of the genome.563
Indeed, DNA affinity (Fig. 6A) and ChIP assays (Fig. 6B) demonstrated that this was the case. The564
DNA affinity assay showed us that overexpressed ARID3B preferentially bound to a region of565
oriLyt that also contains A/T-rich palindromic sequences in addition to a downstream region566
which contained the RTA-responsive element (RRE). Interestingly, it was previously shown that567
many host and viral proteins involved in KSHV reactivation specifically bind these two regions in568
oriLyt (25).569
30
Importantly, ChIP assays not only allowed us to confirm binding in vivo, it also allowed us to ask570
if its interaction was dependent on lytic reactivation. This was an important question as much of571
our data suggested that ARID3B’s inhibitory properties were associated with RTA expression,572
which is silenced during latency; for example, and as mentioned earlier, knockdown of ARID3B573
from latently-infected cells did not appear to stimulate lytic gene expression (suggesting it does574
not have a role in the maintenance of latency). Strikingly, this interaction was indeed dependent575
on reactivation of the lytic cycle, as no binding was observed on the latent genome. This might576
suggest that the chromatinized latent KSHV genome precludes ARID3B access; however, upon577
reactivation, which is associated with removal of nucleosomes, ARID3B can bind. However, it is578
not currently known if ARID3B binding is dependent on chromatin status of DNA. Additionally,579
whether this is dependent on direct DNA binding or it requires PPIs, and if ARID3B blocks580
transcription or DNA replication are still open questions. Nevertheless, this data provides weight581
to the hypothesis that ARID3B specifically responds to reactivation of the lytic cycle from latency582
and inhibits it via interactions with the KSHV genome. We propose that this interaction likely583
competes with oriLyt-associated factors required for reactivation of the lytic cycle (Fig. 7).584
We were surprised to observe that RTA expression induced a number of proteins and pathways585
associated with transcriptional silencing (Tables 1 and 2). Although it will be critical to validate586
these observations, this might not be surprising given that de novo KSHV infection of tissue587
culture cells leads to viral latency, despite an initial burst of lytic cycle-associated gene expression588
(79). Therefore, while RTA drives expression from the viral genome during reactivation, it may589
also induce a number of processes (directly or indirectly) that ultimately silences lytic gene590
expression.591
31
In summary, we have identified a novel cellular protein, ARID3B, which responds to the lytic cycle592
of KSHV, and functions to inhibit it. Lytic cycle-associated induction of negative feedback593
mechanisms is clearly an important feature of herpesvirus biology and is consistent with a virus594
that favors lifelong infection of its host.595
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Figure legends825
FIG 1. Analysis via SILAC coupled to LC-MS/MS of nuclear proteome changes in response to KSHV-826
RTA expression. Flp-In-293 cells were used to develop a cell line with doxycycline-inducible FLAG-827
tagged RTA expression (iRTA-293). (A) Cells were labeled with R10K8 (heavy) or R0K0 (light)828
labelled SILAC media for two weeks. FLAG-RTA expression was induced in heavy-labelled cells for829
12 h and these were fractionated into nuclear and cytoplasmic compartments. Fractionation830
success was validated by immunoblot analysis using the nuclear (Lamin-B1) and cytoplasmic831
(GAPDH) markers. As expected, RTA expression was largely restricted to the nuclear832
compartment, and was only found in dox.-treated cells. (B) FLAG-RTA expression was analyzed833
by confocal immunofluorescence that revealed all Dox.-treated cells were positive for FLAG-RTA834
and Untreated (-Dox; R0K0-labeled cells) were negative for RTA expression, demonstrating tight835
regulation of FLAG-RTA. Scale bar - 10 µm. (C) KEGG pathway analysis of nuclear proteins that836
were upregulated 2-fold or more due to RTA expression, with at least 2 independent peptides837
revealed various cellular pathways associated RTA expression. GO Term – gene ontology term.838
839
FIG 2. RTA enhances ARID3B expression. (A) Doxycycline- (Dox.)-induced expression in iRTA-293840
cells for 12 h and reactivation of the KSHV lytic cycle by the addition of Dox. in TREx-BCBL1-RTA841
cells increased ARID3B expression as measured by qRT-PCR. Error bars represent standard842
deviation from the mean from three independent biological replicates and quantification was843
normalized to GAPDH using the ΔΔCt method. Student’s t-tests were used to determine statistical 844
significance. Three independent experiments were performed for each cell line (B) Reactivation845
38
of the lytic cycle from latently infected iSLK-BAC16 and TREx-BCBL1-RTA cells led to an increase846
in ARID3B protein expression. In this experiment, separate immunoblots were used for the847
detection of RTA (denoted by a line). (C) Quantification of protein expression in (B) (see Materials848
and Methods). Data are derived from two independent experiments and error bars represent849
standard deviation of the mean (calculated from technical replicates within independent850
experiments). * = P < 0.05 (Student’s t-test).851
FIG 3. ARID3B relocalizes to KSHV replication compartments upon reactivation of the lytic cycle.852
(A) Confocal immunofluorescence analysis demonstrated that ARID3B relocalized to discrete,853
RTA-positive foci that resemble replication compartments (white arrows) upon Dox.-induced854
reactivation of the KSHV lytic cycle in TREx-BCBL1-RTA cells. (B) Further evidence suggesting that855
ARID3B relocalized to replication compartments demonstrated by its colocalization with RTA and856
EdU-positive foci (white arrows). EdU is used as a marker of newly replicated viral (57). Scale bar857
- 10 µm.858
FIG 4. ARID3B inhibits KSHV lytic reactivation. (A) Latently infected iSLK-BAC16 cells were859
independently transfected with two separate siRNAs pools targeting ARID3B (or a non-targeting860
scramble control siRNA) for 72 h and then reactivated by addition of dox (a further 24 h; see861
Materials and Methods). RT-qPCR was used to quantify ARID3B, ORF57 and gB levels and the fold862
difference in expression was compared to scramble control using GAPDH levels to normalize863
between samples. Error bars represent standard deviation from the mean from two independent864
experiments, with mean values calculated from the technical replicates of each experiment.865
Statistical analyses demonstrated a significant increase in lytic gene expression in siARID3B-866
treated cells compared to scramble control ** p = <0.0001 (Student’s t-test). (B) Knockdown of867
39
ARID3B led to an enhancement of lytic protein expression. (C) Quantification of (B) (see Materials868
and Methods). (D) Knockdown of ARID3B enhanced viral genome replication. ARID3B siRNA or869
scramble control siRNAs transfection of iSLK-BAC16 cells followed by reactivation of the lytic870
cycle for 72 h led to an increase in viral genome replication, as quantified by qPCR of the KSHV871
ORF57 gene. Cellular GAPDH was used to normalize between samples and error bars represent872
standard deviation from the mean from three independent biological replicates (* p < 0.05). (E)873
Knockdown of ARID3B enhances virion production. Media from iSLK-BAC16 cells that had been874
transfected with siARID3B or scramble control siRNAs were used to infect KSHV-negative875
HEK293T cells. As a measure of infection, RT-qPCR analysis of the KSHV lytic gene ORF57 was876
performed 24 h following infection. Data represent three independent infections in a single877
experiment, and Student’s t-test was used to determine statistical significance (* = P < 0.05). (F)878
Overexpression of FLAG-ARID3B inhibits reactivation of lytic cycle-associated protein expression.879
Expression vector containing FLAG-tagged ARID3B (FLAG-ARID3B) or FLAG-SRAG (used as a880
negative control) were transfected in to iSLK-BAC16 cells for 24 h, followed by Dox.-induced881
reactivation of the KSHV lytic cycle. Cell lysates were harvested 24 h later and subjected to882
immunoblot analysis of lytic proteins ORF57 and mCP (minor capsid protein).883
FIG 5. RTA and ARID3B do not directly interact. Immunoprecipitation assay showing RTA interacts884
with known binding partner ORF59, but not ARID3B. The lytic cycle was induced in ARID3B-885
transfected iSLK-BAC16 cells. Proteins were immunoprecipitated with the indicated antibodies886
followed by immunoblot analysis.887
FIG 6. ARID3B interacts with the KSHV genome in a lytic reactivation-dependent manner. (A) DNA888
affinity assays performed according to (25); biotinylated PCR products spanning oriLyt left of889
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KSHV (GenBank accession number: NC_009333.1) and control DNA amplified from the RTA890
coding region were bound to streptavidin Dynabeads and incubated with lysates from891
reactivated 293T rKSHV.219 cells expressing FLAG-ARID3B. This suggested ARID3B bound these892
sequences with preference for the A/T-rich region. (B) TREx-BCBL1-RTA cells were treated with893
doxycycline for 18 h (w/ Dox) to reactivate the lytic cycle or were left untreated (w/o Dox).894
Samples were subjected to ChIP with an antibody to ARID3B or normal rabbit IgG and primers895
specific for sequences in the A/T-rich region of oriLyt or the RTA coding region. The percentage896
of output versus input DNA was calculated and is presented relative to normal rabbit IgG values897
from unreactivated (w/o Dox) cells (set to 1). Data represent two biological (i.e. independent898
ChIPs) and two technical replicates per ChIP from a single experiment, and values are given as899
the mean ± standard deviation. Student t-tests were used to determine statistical significance.900
FIG 7. A model of how ARID3B inhibits lytic reactivation. Periodic reactivation of KSHV involves901
replication of the viral genome and the production of new virions, a necessary step for the902
maintenance of latency and the pathogenesis of KS (2). Viral DNA replication initiates from the903
cis-acting oriLyt where proteins essential for this process are recruited. These include viral904
proteins RTA, K8 and the six core proteins (DNA polymerase, DNA processivity factor etc.) (80) in905
addition to various cellular trans-acting proteins (25). We hypothesize that during reactivation906
RTA is expressed leading to the enhanced expression of ARID3B and its recruitment to viral907
genomes, specifically AT-rich elements such as those found in oriLyt. ARID3B may compete with908
factors required for reactivation for binding with the KSHV genome in order to modulate the909
levels of reactivation or for the establishment of latency.910






TABLE 1 Top 15 proteins increased in abundance in the nuclear fraction upon RTA expression.
Name Uniprot ID* Fold
increase
Unique
peptides
Sequence
coverage
(%)
PEP** Function*
ATPase family AAA
domain-containing
protein 3B
Q5T9A4-1 53.4 12 19.8 1.90E-79 May play a role in a
mitochondrial network
organization typical for
stem cells.
Cell division cycle-
associated 7-like
protein
Q96GN5-1 15.5 3 9.3 1.68E-18 Transcriptional
repressor.
Transmembrane
protein 43
Q9BTV4 11.9 7 24.8 1.18E-55 May have a role in
maintaining nuclear
envelope structure.
Kinesin-like protein
KIF11
P52732 11.7 37 46.14 6.53E-
283
Motor protein required
for establishing a
bipolar spindle during
mitosis.
BAT2 domain-
containing protein
1
Q9Y520-7 10.8 39 17 1.39E-
164
Unknown.
Centrosomal
protein of 170 kDa
Q5SW79-1 9.6 19 14.3 2.53E-66 Plays a role in
microtubule
organization.
Uncharacterized
protein KIAA1671
Q9BY89-1 9.3 4 2.6 3.61E-11 Unknown.
Upstream of NRAS Q68DF1 9.1 18 26.1 2.26E-
193
May be involved in
translationally coupled
mRNA turnover.
AT-rich interactive
domain-containing
protein 3B
Q8IVW6-1 7.5 8 15.7 2.25E-67 Transcription factor
which may be involved
in neuroblastoma
growth and malignant
transformation.
General
transcription factor
3C polypeptide 2
Q8WUA4-1 7.5 3 5.5 1.88E-10 Required for RNA
polymerase III-mediated
transcription.
Protein LYRIC Q86UE4 7.0 4 7.7 2.99E-14 Activates the NF-κB 
transcription factor.
Cadherin-2 P19022 6.4 3 5.8 2.33E-11 Calcium-dependent cell
adhesion proteins.
Cytospin-A Q69YQ0 6.1 3 3.3 3.88E-10 Involved in cytokinesis
and spindle
organization.
Lethal(3)malignant
brain tumor-like 3
protein
Q96JM7-1 5.7 3 4 3.46E-07 Putative Polycomb
group (PcG) protein.
PcG proteins maintain
the transcriptionally
repressive state of
genes.
Lysine-specific
demethylase 2A
Q9Y2K7-1 5.2 3 2.8 8.35E-08 Histone demethylase
that specifically
demethylates 'Lys-36' of
histone H3. Maintains
heterochromatin.
* Protein information was annotated from the Uniprot database (www.uniprot.org).
** Posterior error probability (a statistical measure for peptide identification – should be below 0.1).
TABLE 2 Ingenuity Pathway Analysis (IPA) of the top canonical pathways associated with RTA
expression (nuclear proteome).
Name P-value
Transcriptional Repression 2.85E-8
Aminoacyl-tRNA Biosynthesis 3.87E-5
Cell Cycle Control of Chromosomal Replication 7.64E-4
Mismatch Repair in Eukaryotes 7.84E-4
Role of BRCA1 in DNA Damage Response 8.12E-4
